Rasburicase in the prevention and treatment of tumour lysis syndrome

Intensive and Critical Care Nursing

Volumn 24, Issue 1, 2008, Pages 59-62

  Mayne, Nicola ^a   Keady, Simon ^a   Thacker, Meera ^b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Allopurinol; Intensive care unit; Rasburicase; Tumour lysis syndrome

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; RASBURICASE; URATE OXIDASE;

HUMAN; INTENSIVE CARE UNIT; REVIEW; TUMOR LYSIS SYNDROME;

ALLOPURINOL; GOUT SUPPRESSANTS; HUMANS; INTENSIVE CARE UNITS; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 38049083061     PISSN: 09643397     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iccn.2007.06.002     Document Type: Review

References (6)

1. Mahmoud H.H., Leverger G., Patte C., et al. Advances in the management of malignancy-associated hyperuricaemia. Br J Cancer 77 4 (1998) 18-20
2. Patte C., Sakiroglu C., Ansoborlo S., et al. Urate-oxidase in the prevention and treatment pf metabolic complications in patients with B-cell lymphoma and leukaemia, treated in the Societe Francais d'Oncologie Pediatrique LMB89 protocol. Ann Oncol 13 (2002) 789-795
3. Pui C.H., Mahmoud H.H., Wley J.M., et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricaemia in patients with leukaemia or lymphoma. J Clin Oncol 19 3 (2001) 697-704
4. Coiffier B., Mounier N., Bologna S., et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricaemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on rasburicase activity in adult lymphoma) study. J Clin Oncol 21 23 (2003) 4402-4406
5. Goldman S.C., Holcenberg J.S., Finkletstein J.Z., et al. A randomised comparison between rasburicase and allopurinol in children with lymphoma or leukaemia at high risk for tumour lysis. Blood 97 10 (2001) 2998-3003
6. Bosly A., Sonet A., Ross Pinkerton C., et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricaemia in patients with cancer. Report of an international compassionate use study. Cancer 98 5 (2003) 1048-1054